Trial Profile
Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- 10 Jul 2023 Status changed from recruiting to completed.
- 07 Nov 2022 Results assessing the effect of evolocumab on vascular function and structure in patients with cardiovascular disease presented at the American Heart Association Scientific Sessions 2022
- 04 May 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2021.